CERo Therapeutics Holdings, Inc. CERO
0.01
0.00
0.00%
as of 25 Sep
- Market cap
- $140.0K
- P/E
- 0.0×
Follow CERO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.30 | 0.50 | 0.56 | 1.38 | 1.38 | 13.87 | 13.87 | — |
Net Debt/EBITDA |
0.10 | 0.22 | 0.01 | (0.06) | 14.28 | 3.31 | 3.31 | — |
Debt/Assets |
0.00% | 0.00% | 30.33% | 1.53% | 1.53% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | (0.04) | (0.06) | 0.26 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.17 | 1.16 | 0.79 | 1.64 | 1.64 | 2.21 | 2.21 | — |
Capex/Depreciation |
0.46 | 0.00 | 0.00 | — | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 1,074.49% | 47.06% | 27.48% | 15.65% | 25.67% | (0.39%) | 0.00% | — | |
| (1,940.02%) | (195.70%) | (30.70%) | (1.58%) | (0.60%) | (0.18%) | (0.35%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
1,564.16% | 350.94% | 1,277.76% | (5.75%) | (5.75%) | (24.98%) | (24.98%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | — | — | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | — | — | — | — |
Free Cash Flow per Share |
(3.68) | (445.38) | (19,300.00) | (474.87) | (0.16) | (303.09) | (0.03) | — |
Cash per Share |
0.39 | 114.73 | 5,337.67 | 206.91 | 6.23 | 477.65 | 0.05 | — |
Shareholders Equity per Share |
(1.29) | (65.33) | (140,192.33) | (4,782.70) | 0.36 | (3,334.74) | 7.43 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(1.29) | (65.33) | (140,192.33) | (4,782.70) | 0.36 | (3,334.74) | 7.43 | — |
Free Cash Flow |
(15.58) | (12.92) | (5.79) | (1.09) | (1.09) | (0.70) | (0.70) | — |
Working Capital |
(6.35) | (3.69) | (1.54) | 11.62 | 11.62 | 1.26 | 1.26 | — |
Capital Expenditures |
0.50 | — | — | — | — | — | — | — |
Net Current Asset Value |
(6.35) | (4.39) | (45.21) | (11.00) | 2.47 | (186.39) | (7.89) | — |
| Other line items | ||||||||
Quick Ratio |
0.18 | 0.45 | 0.46 | 0.02 | 1.37 | 11.20 | 11.20 | — |
Depreciation/Fixed assets |
4.41 | 2.20 | 1.16 | — | — | — | — | — |
Cash ROIC |
431.45% | (938.53%) | 17.37% | 11.06% | (2.41%) | 10.61% | (0.41%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.80) | (445.38) | (19,300.00) | (474.87) | (0.16) | (303.09) | (0.03) | — |
Capex per Share |
0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
6.04 | 3.09 | 1.66 | 0.83 | — | — | — | — |
Average Assets |
4.92 | 5.67 | 23.75 | 42.37 | 111.22 | 180.08 | 90.04 | — |
Average Common Equity |
(8.89) | (23.56) | (26.53) | (4.27) | (2.60) | 81.58 | — | — |
Capex to Sales |
0.00 | — | — | — | — | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates